Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
NCL 00017509 is a potent and reversible NIMA related kinase 2 (Nek2) inhibitor (IC50 = 56 nM). Induces increased mitotic abnormalities and mitotic delay. Cell permeable and active in vivo. In mice bearing pancreatic tumors, NCL 00017509 decreases PD-L1 expression and induces an anticancer immune response.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 292.3. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.42 mL||17.11 mL||34.21 mL|
|5 mM||0.68 mL||3.42 mL||6.84 mL|
|10 mM||0.34 mL||1.71 mL||3.42 mL|
|50 mM||0.07 mL||0.34 mL||0.68 mL|
References are publications that support the biological activity of the product.
Lebraud et al (2014) Model system for irreversible inhibition of Nek2: thiol addition to ethynylpurines and related substituted heterocycles. Org.Biomol.Chem. 12 141 PMID: 24213855
Zhang et al (2021) NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat.Commun. 12 4536 PMID: 34315872
If you know of a relevant reference for NCL 00017509, please let us know.
Keywords: NCL 00017509, NCL 00017509 supplier, NCL00017509, NIMA, related, kinase, 2, NEK2, inhibitors, inhibits, mitotic, delay, Nek2, Kinase, 5150, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for NCL 00017509 include:
Zhang et al (2021) NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 12 4536 PMID: 34315872
Do you know of a great paper that uses NCL 00017509 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review NCL 00017509 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.